NIH proposal to change Recombinant DNA Advisory Committee rule provisionally accepted.
GENE THERAPY PROTOCOL APPROVAL AUTHORITY WOULD BE SOLELY FDA RESPONSIBILITY, under a proposal provisionally approved by the National Institutes of Health's Recombinant DNA Advisory Committee Dec. 9. RAC gave provisional approval to NIH's latest proposal to restructure the policy body, as outlined in a Nov. 22 Federal Register notice. Under the proposal, RAC's membership would be reduced from 25 to 15 and the committee would cede sole protocol approval authority to FDA ("The Pink Sheet" Nov. 25, T&G-6).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth